Differential responses to therapy in Hispanic NSCLC patients with EGFR, KRAS, or TP53 mutations.

被引：0

作者：

Basher, Fahmin

Saravia, Diana

Lopes, Gilberto

机构：

[1] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA

[2] Cleveland Clin Florida, Weston, FL USA

[3] Univ Miami, Miller Sch Med, Miami, FL 33136 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.e21027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21027

引用

页数：3

共 50 条

[1] Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Roberto Ruiz-Cordero
Junsheng Ma
Abha Khanna
Genevieve Lyons
Waree Rinsurongkawong
Roland Bassett
Ming Guo
Mark J. Routbort
Jianjun Zhang
Ferdinandos Skoulidis
John Heymach
Emily B. Roarty
Zhenya Tang
L. Jeffrey Medeiros
Keyur P. Patel
Rajyalakshmi Luthra
Sinchita Roy-Chowdhuri
[J]. BMC Cancer, 20
[2] Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
Ruiz-Cordero, Roberto
Ma, Junsheng
Khanna, Abha
Lyons, Genevieve
Rinsurongkawong, Waree
Bassett, Roland
Guo, Ming
Routbort, Mark J.
Zhang, Jianjun
Skoulidis, Ferdinandos
Heymach, John
Roarty, Emily B.
Tang, Zhenya
Medeiros, L. Jeffrey
Patel, Keyur P.
Luthra, Rajyalakshmi
Roy-Chowdhuri, Sinchita
[J]. BMC CANCER, 2020, 20 (01)
[3] KRAS, BRAF and TP53 mutations in Romanian colorectal cancer patients
Murarasu, Daniela
Puiu, Liliana
Mihalcea, Corina
Cinca, Sabin
Simion, Laurentiu
[J]. JOURNAL OF BIOTECHNOLOGY, 2016, 231 : S92 - S92
[4] EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients
Wang, Zhen
Wu, Yi Long
Zhang, Guo Chun
Zhou, Qing
Xu, Chong Rui
Guo, Ai Lin
[J]. ONKOLOGIE, 2008, 31 (04): : 174 - 178
[5] Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.
Ulivi, Paola
Canale, Matteo
Petracci, Elisabetta
Chiadini, Elisa
Dazzi, Claudio
Capelli, Laura
Gamboni, Alessandro
Casanova, Claudia
Papi, Maximilian
Mariotti, Marita
De Luigi, Nicoletta
Burgio, Marco Angelo
Ludovini, Vienna
Bennati, Chiara
Chiari, Rita
Calistri, Daniele
Crino, Lucio
Amadori, Dino
Delmonte, Angelo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
Scoccianti, Chiara
Vesin, Aurelien
Martel, Ghislaine
Olivier, Magali
Brambilla, Elisabeth
Timsit, Jean-Francois
Tavecchio, Luca
Brambilla, Christian
Field, John K.
Hainaut, Pierre
[J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (01) : 177 - 184
[7] Cytotoxic Therapy Provides a Fitness Advantage to Rare HSPCs Harboring Somatic TP53 Mutations.
Wong, T. N.
Ramsingh, G.
Young, A. L.
Klco, J. M.
Miller, C. A.
Petti, A.
Demeter, R.
Welch, J. S.
Helton, N. M.
Li, T.
Lamprecht, T. L.
Fulton, R. S.
Heath, S.
Ding, L.
Mardis, E. R.
Westervelt, P.
DiPersio, J. F.
Walter, M. J.
Graubert, T. A.
Ley, T. J.
Wilson, R. K.
Druley, T. E.
Link, D. C.
[J]. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2016, 57 : S54 - S54
[8] TP53 Mutations as Mechanisms of Primary and Acquired Resistance to Tyrosine Kinase Inhibitors in Patients With EGFR-Mutated NSCLC
Canale, M.
Ludovini, V.
Crino, L.
Dazzi, C.
Chiadini, E.
Capelli, L.
Papi, M.
Mariotti, M.
De Luigi, N.
Minuti, G.
Calistri, D.
Baglivo, S.
Chiari, R.
Bonafe, M.
Delmonte, A.
Ulivi, P.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S591 - S591
[9] TP53 Mutations are Present in Targeted NGS Profiles from EGFR Wild type, NSCLC Patients with Poor Prognosis
Mellet, H.
Jackson, L.
Hahn, W.
Dupuis, N.
Weaver, A.
Greer, J.
Pestano, G.
[J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2016, 18 (06): : 1012 - 1012
[10] Histopathological features of breast cancers in women with germline TP53 mutations.
Masciari, S.
Kandel, M.
Digianni, L.
Dillon, D.
Li, F.
Garber, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 548S - 548S

← 1 2 3 4 5 →